2nd hall

Selected poster presentations					
PA001	Day 1	11:10-12:10	Genetical and geographical features of hereditary transthyretin amyloidosis in Japan	Yamashita, Taro	Kumamoto, Japan
PA002	Day 1	11:10-12:10	An amyloid-selective human-derived antibody as a candidate therapeutic for ATTR amyloidosis diseases	Michalon, Aubin	Schlieren, Switzerland
PA003	Day 1	11:10-12:10	Serum free light chain abnormalities in systemic transthyretin amyloidosis	Sarosiek, Shayna	Boston, United States
PA056	Day 1	11:10-12:10	Amyloid of the lung and bronchi	Baumgart, Julius-V.	Kiel, Germany
PA057	Day 1	11:10-12:10	Coexistence of transthyretin- and Aβ-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis	Sakai, Kenji	Kanazawa, Japan
PA058	Day 1	11:10-12:10	Mortality from Amyloidosis in the United States: 1979-2015	Alexander, Kevin	Mountain View, United States

3rd floor

PA001	Day 1	13:30-14:30	Genetical and geographical features of hereditary transthyretin amyloidosis in Japan	Yamashita, Taro	Kumamoto, Japan
PA002	Day 1	13:30-14:30	An amyloid-selective human-derived antibody as a candidate therapeutic for ATTR amyloidosis diseases	Michalon, Aubin	Schlieren, Switzerland
PA003	Day 1	13:30-14:30	Serum free light chain abnormalities in systemic transthyretin amyloidosis	Sarosiek, Shayna	Boston, United States
PA004	Day 1	13:30-14:30	Rare cases of onset with cardiac involvement in a large cohort of patients with Val30Met transthyretin amyloidosis from Majorca focus	Ripoll-Vera, Tomas	Palma, Spain
PA005	Day 1	13:30-14:30	Cardiac involvement in a large cohort of patients with Val30Met transthyretin amyloidosis from Majorca focus	Ripoll-Vera, Tomas	Palma, Spain
PA006	Day 1	13:30-14:30	Structural insights into a unique duplication mutation in transthyretin, TTR Glu51_ Ser52dup, associated with aggressive hereditary amyloidosis	Klimtchuk, Elena S	Boston, United States
PA007	Day 1	13:30-14:30	Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation	Huang, Guannan	Kumamoto, Japan
PA008	Day 1	13:30-14:30	Cardiac and Peripheral Vasomotor Autonomic Functions in Late-onset Hereditary ATTR Amyloidosis with Val30Met Mutation	Nakamura, Tomohiko	Nagoya, Japan
PA009	Day 1	13:30-14:30	ATTR-specific Expression of Chaperones in Hepatocyte-like Cells	Niemietz, Christoph	Münster, Germany
PA010	Day 1	13:30-14:30	In Vitro Inhibition of TTR Oligomerization by Tafamidis	Niemietz, Christoph	Münster, Germany

PA011	Day 1	13:30-14:30	Sural nerve injury in TTR-FAP: First correlation study between magnetic resonance neurography and traditional clinical and pathological diagnostics	Kollmer, Jennifer	Heidelberg, Germany
PA012	Day 1	13:30-14:30	Experiences from an open-label diflunisal trial (DFNS01) and the impact of amyloid fibril composition in hereditary transthyretin amyloidosis	Wixner, Jonas	Umeå, Sweden
PA013	Day 1	13:30-14:30	A ligand conjugated antisense oligonucleotide for the treatment of Transthyretin amyloidosis (ATTR)	Guo, Shuling	Carlsbad, United States
PA014	Day 1	13:30-14:30	Diagnostic and prognostic value of native T1 and ECV in ATTR amyloidosis	Martinez-Naharro, Ana	London, United Kingdom
PA015	Day 1	13:30-14:30	Cardiac involvement after liver transplantation in patients with Val30Met transthyretin amyloidosis from Majorca focus	Ripoll-Vera, Tomas	Palma, Spain
PA016	Day 1	13:30-14:30	Late Gadolinium Enhancement in the Left Atrium Predicts Wild-type Transthyretin Amyloidosis-associated Cardiomyopathy in Patients with Left Ventricular Hypertrophy	Izumiya, Yasuhiro	Kumamoto, Japan
PA017	Day 1	13:30-14:30	The diagnostic value of unspecific clinical features in the follow-up of Val30Met TTR mutation carriers	Dohrn, Maike F	Aachen, Germany
PA018	Day 1	13:30-14:30	Misdiagnosis in late versus early onset hATTR amyloidosis patients: experience from a reference center	Conceicao, Isabel	Lisboa, Portugal
PA019	Day 1	13:30-14:30	Correlation between Sudoscan and COMPASS 31: assessment of autonomic dysfunction on hATTR V30M patients	Conceicao, Isabel	Lisboa, Portugal
PA020	Day 1	13:30-14:30	Rapid detection of mutated transthyretin using direct MALDI-TOF MS	Nomura, Toshiya	Kumamoto, Japan
PA021	Day 1	13:30-14:30	Late-onset familial amyloid polyneuropathy (FAP ATTR Val30Met) may manifest as severe dysautonomia and sick sinus syndrome at its onset in a non-endemic areas	Hirohisa, Hirano	Osaka, Japan
PA022	Day 1	13:30-14:30	A transgenic Caenorhabditis elegans expressing transthyretin as a model in transthyretin amyloidosis	Tsuda, Yukimoto	Kumamoto, Japan
PA023	Day 1	13:30-14:30	The Transthyretin Amyloidosis Outcomes Survey (THAOS): 10 year update	Waddington Cruz, Marcia	Rio de Janeiro, Brazil
PA024	Day 1	13:30-14:30	Clinical and demographic characteristics of subjects with the Thr60Ala mutation enrolled in the Transthyretin Amyloidosis Outcomes Survey	Grogan, Martha	Rochester, United States
PA025	Day 1	13:30-14:30	The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan	Yoshiki, Sekijima	Matsumoto, Japan
PA026	Day 1	13:30-14:30	Longitudinal modeling of disease-progression in transthyretin familial polyneuropathy with tafamidis	Steve, Riley	Sandwich, United Kingdom
PA027	Day 1	13:30-14:30	Effect of Panretinal Photocoagulation on Ocular Amyloidosis Associated with Transthyretin-Familial Amyloidotic Polyneuropathy : 5-Year Follow-Up	Kawaji, Takahiro	Arao, Japan
PA028	Day 1	13:30-14:30	Transthyretin Fragments in Peripheral Blood Cells	Matsumoto, Sayaka	Kumamoto, Japan
PA029	Day 1	13:30-14:30	Late-onset sporadic transthyretin Val30Met-associated familial amyloid polyneuropathy presenting as chronic undetermined polyneuropathy	Suzuki, Miki	Tokyo, Japan

PA030	Day 1	13:30-14:30	Analysis of the non-coding rs3764479 mutation in the proximal promoter of the transthyretin gene	Boldbaatar, Batbold	Boston, United States
PA031	Day 1	13:30-14:30	Amyloid formation and toxicity of fragmented transthyretin	Ueda, Mitsuharu	Kumamoto, Japan
PA032	Day 1	13:30-14:30	First nationwide survey on systemic wild-type ATTR amyloidosis in Japan	Sekijima, Yoshiki	Matsumoto, Japan
PA033	Day 1	13:30-14:30	Transthyretin amyloidosis in patients with undifferentiated heart failure	Chang, Ian C.	Rochester, United States
PA034	Day 1	13:30-14:30	Guidelines for the suspicion and diagnosis of ATTR amyloidosis: a collaboration between the Amyloidosis Research Consortium and the amyloidosis physician community	Lousada, Isabelle	Newton, United States
PA035	Day 1	13:30-14:30	Biochemical pathomechanism of progression of Ocular and CNS amyloidosis in liver-transplanted hereditary ATTR amyloidosis patients	Yazaki, Masahide	Matsumoto, Japan
PA036	Day 1	13:30-14:30	Pupillary autonomic dysfunction as an early biomarker in patients with hereditary transthyretin amyloidosis	Masuda, Teruaki	Kumamoto, Japan
PA037	Day 1	13:30-14:30	A Japanese patient with late-onset cardiomyopathy: The first Asian case of V122I hereditary ATTR amyloidosis	Yazaki, Masahide	Matsumoto, Japan
PA038	Day 1	13:30-14:30	A descriptive analysis of subjects with the Val122Ile mutation from the Transthyretin Amyloidosis Outcomes Survey	Maurer, Mathew	New York, United States
PA039	Day 1	13:30-14:30	Impact of non-cardiac baseline characteristics on survival in transthyretin familial amyloid polyneuropathy	González Duarte, Alejandra	Mexico City, Mexico
PA040	Day 1	13:30-14:30	Collagen type IV in brain vessels of an AD mouse model: modulation by Transthyretin?	Cardoso, Isabel	Porto, Portugal
PA041	Day 1	13:30-14:30	Altered autophagy-related proteins in the hearts of hTTR V30M transgenic mice	Teixeira, Cristina	Porto, Portugal
PA042	Day 1	13:30-14:30	Impairment of the immune response in Familial Amyloid Polyneuropathy: a role for Cathepsin E	Saraiva, Maria	Porto, Portugal
PA043	Day 1	13:30-14:30	Ala97Ser mutation is common among ethnic Chinese Malaysians with Transthyretin Familial Amyloid Polyneuropathy	Low, Soon Chai	Kuala Lumpur, Malaysia
PA044	Day 1	13:30-14:30	Burden of hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (hATTR-PN) in patients enrolled in the phase 3 study NEURO-TTR	Berk, John	Boston, United States
PA045	Day 1	13:30-14:30	Inotersen improves Norfolk quality of life–diabetic neuropathy (Norfolk QOL-DN) measures in patients with hereditary transthyretin amyloidosis (hATTR) polyneuropathy (PN) in the phase 3 study NEURO-TTR	Polydefkis, Michael J.	Baltimore, United States
PA046	Day 1	13:30-14:30	Open label extension of the phase 3 NEURO-TTR study to assess the long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis (hATTR)	Brannagan, Thomas	New York, United States
PA047	Day 1	13:30-14:30	Inotersen improves quality of life (QOL) in patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (PN) and cardiomyopathy (CM): results of the phase 3 study NEURO-TTR	Maurer, Matthew S.	New York, United States
PA048	Day 1	13:30-14:30	Safety and efficacy of inotersen in patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (hATTR-PN) in the NEURO-TTR study	Gertz, Morie A	Rochester, United States

PA049	Day 1	13:30-14:30	An autopsy case of familial amyloid polyneuropathy (FAP) with novel transthyretin mutation (ATTR, Lys80Arg) showing compound heterogeneous pathological mutations relieve its symptoms	Miyamoto, Yuka	Nankoku, Japan
PA050	Day 1	13:30-14:30	Transthyretin Glu54Leu a previously unknown mutation within the Swedish population is associated with amyloid cardiomyopathy	Hellman, Urban	Umeå, Sweden
PA051	Day 1	13:30-14:30	Carpal tunnel Syndrome as an early sign to diagnose Cardiac Amyloidosis	Garcia-Pavia, Pablo	Madrid, Spain
PA052	Day 1	13:30-14:30	Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis	Takashio, Seiji	Kumamoto, Japan
PA053	Day 1	13:30-14:30	Cardiac disorders in THAOS subjects with V30M transthyretin amyloidosis	Damy, Thibaud	Créteil, France
PA054	Day 1	13:30-14:30	Clinical Pathway to Screen for Cardiac Amyloidosis in Heart Failure with Preserved Ejection Fraction	Fajardo, Johana R.	Baltimore, United States
PA055	Day 1	13:30-14:30	Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis	Rubin, Jonah	Washington Heights, United States
PA056	Day 1	13:30-14:30	Amyloid of the lung and bronchi	Baumgart, Julius-V.	Kiel, Germany
PA057	Day 1	13:30-14:30	Coexistence of transthyretin- and Aβ-type cerebral amyloid angiopathy in a patient with hereditary transthyretin V30M amyloidosis	Sakai, Kenji	Kanazawa, Japan
PA058	Day 1	13:30-14:30	Mortality from Amyloidosis in the United States: 1979-2015	Alexander, Kevin	Mountain View, United States
PA059	Day 1	13:30-14:30	Understanding the Mechanism of Amyloid Formation in novel Hemoglobins, Characterization by Biochemical & Biophysical methods and investigating the role of Amyloids in Alzheimer's	Kant, Ravi	New Delhi, India
PA060	Day 1	13:30-14:30	Proteomic Profiles of Mouse AApoAII Amyloid Fibrils suggest the Involvement of Lipoproteins in the Pathology of Amyloidosis	Miyahara, Hiroki	Matsumoto, Japan
PA061	Day 1	13:30-14:30	Levels of IAPP are associated with retinal vascular changes in patients with Alzheimer's disease and non-demented controls.	Schultz, Nina	Malmö, Sweden
PA062	Day 1	13:30-14:30	Increased activity of astrocytic alpha-amylase in prescence of amyloid beta	Byman, Elin	Malmö, Sweden
PA063	Day 1	13:30-14:30	Clinical pharmacology of miridesap in Japanese and non-Japanese subjects to enable dezamizumab treatment in systemic amyloidosis	Doi, Yohei	Tokyo , Japan
PA064	Day 1	13:30-14:30	Effects of Iowa (G26R) mutation on fibril formation by an amyloidogenic N-terminal fragment of apoA-I	Mizuguchi, Chiharu	Kyoto, Japan
PA065	Day 1	13:30-14:30	Localized Amyloidosis in Rat Mammary Gland	Murakami, Tomoaki	Fuchu, Japan
PA066	Day 1	13:30-14:30	Amyloid fibril formation of immunoglobulin light chain peptide from IHC-negative AL amyloidosis and its inhibition by doxycycline and epigallocatechin	Hata, Hiroyuki	Kumamoto, Japan
PA067	Day 1	13:30-14:30	Amyloid myopathy: Diagnosis, clinical presentation, pathology, and amyloid imaging findings of this rare myopathy associated with systemic immunoglobulin light-chain (AL) amyloidosis	Katoh, Nagaaki	Matsumoto, Japan

PA068	Day 1	13:30-14:30	CMR to assess treatment response in patients with cardiac AL amyloidosis - the ALCHEMY trial	Martinez-Naharro, Ana	London, United Kingdom
PA069	Day 1	13:30-14:30	Differences in protein concentration dependence for nucleation and elongation in light chain amyloid formation	Blancas-Mejia, Luis M	Rochester, United States
PA070	Day 1	13:30-14:30	The Effect of Delayed Diagnosis on Survival Rates in Patients with Light Chain Cardiac Amyloidosis	Lim, Mingi	Seoul, Korea
PA071	Day 1	13:30-14:30	RAIN (Renal AL Amyloid Involvement and NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects with Systemic AL Amyloidosis and Persistent Renal Involvement	Varga, Cindy	Newton, United States
PA072	Day 1	13:30-14:30	Amyloidosis Research Consortium Cardiac Amyloidosis Survey: Results from Patients with AL and ATTR amyloidosis and Their Caregivers	Lousada, Isabelle	Newton, United States
PA073	Day 1	13:30-14:30	Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis	Quintana, Luis F.	Barcelona, Spain
PA074	Day 1	13:30-14:30	Local AL amyloidosis is associated with an on-site clonal plasmacytic differentiated B-cell population - Report on 20 cases of diverse anatomical origin	Rücken, Christoph	Kiel, Germany
PA075	Day 1	13:30-14:30	Characterization and quantification of peripheral neuropathy in AL amyloidosis by magnetic resonance neurography	Kollmer, Jennifer	Heidelberg, Germany
PA076	Day 1	13:30-14:30	Baseline patient-reported outcomes in light chain amyloidosis patients enrolled on an interventional clinical trial	D'Souza, Anita	Milwaukee, United States
PA077	Day 1	13:30-14:30	Role of liver transplantation in the treatment of Fibrinogen Aa-chain amyloidosis	Stangou, Arie J	Birmingham, UK
PA078	Day 1	13:30-14:30	Immunoglobulin light chain amyloidosis mutational landscape revealed by exome sequencing	Kufova, Zuzana	Ostrava-Poruba, Czech
PA079	Day 1	13:30-14:30	Heavy chain amyloidosis in gastroduodenal biopsies -the histopathological features-	Ichimata, Shojiro	Matsumoto, Japan
PA080	Day 1	13:30-14:30	Detection of Circulating Clonal Plasma Cells Using Next Generation Sequencing in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Novel Discovery	Varga, Cindy	Newton, United States
PA081	Day 1	13:30-14:30	The Presence of AL amyloidosis is associated with Poor Survival in Patients with Lymphoplasmacytic Lymphoma	Jang Ho Cho	Seoul, Korea
PA082	Day 1	13:30-14:30	Validating Modern Response Criteria with a Historical Clinical Trial Cohort	Warsame, Rahma	Rochester, United States
PA083	Day 1	13:30-14:30	Pooled Analysis of Phase II studies of Immunomodulating drugs in Light Chain Amyloidosis: Update on Outcomes	Warsame, Rahma	Rochester, United States
PA084	Day 1	13:30-14:30	Patient-reported distress in systemic light chain amyloidosis is prevalent but not determined by severity of disease	D'Souza, Anita	Milwaukee, United States
PA085	Day 1	13:30-14:30	A Mixed Methods Study of the Journey to Diagnosis Among Patients With Light Chain Amyloidosis	Quock, Tiffany	South San Francisco, United States
PA086	Day 1	13:30-14:30	Real-world burden of comorbidities in patients with newly diagnosed AL amyloidosis	Quock, Tiffany	South San Francisco, United States

PA087	Day 1	13:30-14:30	Real-world healthcare utilization and costs in patients with newly diagnosed AL amyloidosis	Quock, Tiffany	South San Francisco, United States
PA088	Day 1	13:30-14:30	Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study	Sanchorawala, Vaishali	Boston, United States
PA089	Day 1	13:30-14:30	Phase 3 study of cyclophosphamide, bortezomib, and dexamethasone with or without daratumumab in patients with newly diagnosed amyloid light chain amyloidosis: AMY3001 (ANDROMEDA)	Comenzo, Raymond	Boston, United States
PA090	Day 1	13:30-14:30	Minimal residual disease in systemic AL amyloidosis: application of molecular methods for clonal gene detection and quantification in bone marrow specimens	Zhou, Ping	Bostion, United States
PA091	Day 1	13:30-14:30	Seeking AL amyloidosis Very Early: The SAVE trial – identifying clonal λ light chain genes in patients with λ MGUS or λ smoldering multiple myeloma	Zhou, Ping	Boston, United States
PA092	Day 1	13:30-14:30	Significant albuminuria (amyloidosis/ monoclonal immunoglobulin deposition disease type) in multiple myeloma with severe renal impairment: a retrospective analysis	Marumo, Yoshiaki	Nagoya, Japan
PA093	Day 1	13:30-14:30	Improving Safety of Autologous Hematopoietic Stem Cell Transplant in Patients with Light Chain (AL) Amyloidosis	Gutierrez-Garcia, Gonzalo	Barcelona, Spain
PA094	Day 1	13:30-14:30	Modified high-dose melphalan and stem cell transplantation in AL amyloidosis: Experience of 22 years	Nguyen, Vina P.	Boston, United States
PA095	Day 1	13:30-14:30	Mechanistic studies on aggregation of immunoglobulin light chain variable domain	Ramirez-Alvarado, Marina	Rochester, United States
PA096	Day 1	13:30-14:30	Incidence and Prevalence of Cardiac Amyloidosis in the United States	Gilstrap, Lauren	Sudbury , United States
PA097	Day 1	13:30-14:30	The Prognostic Significance of Holter monitor Findings in Patients with Light Chain Amyloidosis	Sidana, Surbhi	Rochester, United States
PA098	Day 1	13:30-14:30	Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis (AL)	Sidana, Surbhi	Rochester, United States
PA099	Day 1	13:30-14:30	Cardiac manifestations in Finnish gelsolin amyloidosis	Mustonen, Tuuli	Espoo, Finland
PA100	Day 1	13:30-14:30	An unusual case of ANP amyloid	Kaul, Risheek	Cleveland, Ohio, United States
PA101	Day 1	13:30-14:30	Intramyofiber amyloid deposits of transgenic mice overexpressing mutant Matrin 3 are involved in the pathogenesis of Vocal Cord Pharyngeal Distal Myopathy.	Hara, Kentaro	Kumamoto, Japan
PA102	Day 1	13:30-14:30	Mechanism of the insulin resistance at the site of insulin amyloidoma	Nakamura, Makoto	Kumamoto, Japan
PA103	Day 1	13:30-14:30	Analyses of prostatic corpora amylacea	Kanenawa, Kyosuke	Kumamoto, Japan
PA104	Day 1	13:30-14:30	Positive Family History Decreases Diagnosis Time by Over 200%	Brown, Emily	Baltimore, United States
PA105	Day 1	13:30-14:30	Suppressing the progression of mouse AApoAII amyloidosis by daily supplementation with oxidative stress inhibitors	Dai, Jian	Matsumoto, Japan

PA106	Day 1	13:30-14:30	Molecular dynamics simulations for disruption of Aβ amyloid fibrils	Okumura, Hisashi	Okazaki, Japan
PA107	Day 1	13:30-14:30	Amyloidosis-inducing Activity of Blood Components in Mouse AApoAII Amyloidosis	Higuchi, Keiichi	Matsumoto, Japan
PA108	Day 1	13:30-14:30	Association of Dialysis-Related Amyloidosis with Lower Quality of Life in Patients on Hemodialysis More Than 10 Years: The Kyushu DialysisRelated Amyloidosis Study	Tsuruya, Kazuhiko	Fukuoka, Japan
PA109	Day 1	13:30-14:30	Metabolomics analysis: searching for biomarkers for Gelsolin amyloidosis	Anan, Intissar	Umeå, Sweden
PA110	Day 1	13:30-14:30	Clinical differences between sporadic inclusion body myositis with and without intramuscular amyloid-like deposits	Yamashita, Satoshi	Kumamoto, Japan
PA111	Day 1	13:30-14:30	Nationwide survey of 199 patients with reactive amyloid A amyloidosis in Japan	Okuda, Yasuaki	Matsuyama, Japan
PA112	Day 1	13:30-14:30	Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis	Kuroda, Takeshi	Niigata, Japan
PA113	Day 1	13:30-14:30	Does AA Amyloid change the microbiome? First hints from the European brown hare (Lepus europaeus)	Posautz, Annika	Vienna, Austria
PA114	Day 1	13:30-14:30	Intraventricular septum thickness (IVST) independently increases according to the decline of eGFR in AA amyloidosis.	Nishi, Shinichi	Kobe, Japan
PA115	Day 1	13:30-14:30	Monoclonal gammopathy of clinical significance about a case of pulmonary nodular amyloidosis	Di Prinzio, Gianfranco	Bruxelles, Belgium
PA116	Day 1	13:30-14:30	Structural Basis of Serum Amyloid A interactions with Lipids and the Functional Implications in Lipid Homeostasis and Amyloid Progression	Frame, Nicholas M	Boston, United States
PA117	Day 1	13:30-14:30	Amyloid storm in amyloid A amyloidosis	Olga Lesya Kukuy	Tel-Aviv, Israel
PA118	Day 1	13:30-14:30	Amyloid A amyloidosis secondary to rheumatoid arthritis may be treatable but is still difficult to manage in daily clinical practice	Nakamura, Tadashi	Kumamoto, Japan
PA119	Day 1	13:30-14:30	Carbamylation of human serum amyloid A	Kawaguchi, Kohei	Shimotsuke, Japan
PA120	Day 1	13:30-14:30	Experimental transmission of AA amyloidosis in the European brown hare (Lepus europaeus) – First results	Posautz, Annika	Vienna, Austria
PA121	Day 1	13:30-14:30	Interactions of human apolipoprotein A-I with component of the extracellular matrix, probable role in amyloidosis	Rosu, Silvana	Buenos Aires, Argentina
PA122	Day 1	13:30-14:30	Species in the aggregation pathways of human apolipoprotein A-I amyloidosi	Ramella, Nahuel A	Buenos Aires, Argentina